Comparative Pharmacology
Head-to-head clinical analysis: SUFENTA PRESERVATIVE FREE versus XARTEMIS XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUFENTA PRESERVATIVE FREE versus XARTEMIS XR.
SUFENTA PRESERVATIVE FREE vs XARTEMIS XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sufentanil is a synthetic opioid analgesic that acts as a selective agonist at mu-opioid receptors in the central nervous system, leading to activation of descending pain pathways and inhibition of nociceptive transmission.
XARTEMIS XR is a combination of oxycodone (a full mu-opioid receptor agonist) and acetaminophen (a centrally acting analgesic with antipyretic properties via cyclooxygenase inhibition).
1-2 mcg/kg IV initially, then 0.15-0.3 mcg/kg/min IV infusion; doses up to 8 mcg/kg for anesthesia induction.
1 tablet (oxycodone 7.5 mg / acetaminophen 325 mg) orally every 12 hours; maximum 2 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5-3.5 hours in adults, 3-4 hours in neonates; clinical context: context-sensitive half-life increases with infusion duration (e.g., ~30 minutes after 2-hour infusion, ~45 min after 8-hour infusion).
Oxycodone: 5.3-6.6 hours (immediate-release), extended-release formulation shows prolonged absorption with apparent half-life ~7.2-9.6 hours; naloxone: 2-3 hours.
Renal (metabolites, <1% unchanged) and biliary; sufentanil is extensively metabolized in liver via N-dealkylation and O-demethylation, with metabolites primarily excreted in urine (approximately 80%) and feces (approximately 20%).
Renal: oxycodone and metabolites ~8.8% free oxycodone, ~8.8% noroxycodone, ~33% conjugated metabolites; naloxone: extensive hepatic metabolism, <1% excreted unchanged in urine. Fecal: naloxone metabolites ~17%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic